A Randomized, Open Labelled Trial of Continuation of Adefovir Plus Lamivudine Versus Switching to Adefovir Plus Entecavir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Adefovir Plus Lamivudine.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Entecavir (Primary) ; Adefovir; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms CAESAR
- Sponsors Asan Medical Center
Most Recent Events
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2010 The treatment duration changed from 52 weeks to 104 weeks according to ClinicalTrials.gov record.
- 02 Dec 2010 Planned End Date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.